Related Experiment Video
Updated: May 28, 2026

Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques
Published on: March 13, 2015
Conjugated Hyperbilirubinemia in Early Infancy: Rethinking Diagnostic Cut-Offs-A Retrospective Analysis
Daniel Pfurtscheller1, Carola Ganzer1, Ena Suppan1
1Division of Neonatology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, 8036 Graz, Austria.
Insights
Combining absolute and relative conjugated bilirubin (CB) thresholds significantly improves early detection of neonatal cholestatic liver disease (CLD). This dual approach enhances diagnostic efficiency by maintaining high sensitivity and reducing unnecessary investigations in infants.
Area of Science:
- Neonatology
- Pediatric Gastroenterology
- Clinical Chemistry
Background:
- Conjugated hyperbilirubinemia in infants signals potential hepatobiliary dysfunction.
- Early diagnosis of cholestatic liver disease (CLD), especially biliary atresia, is critical.
- Current guidelines use an absolute threshold for conjugated bilirubin (CB) ≥ 1 mg/dL.
Purpose of the Study:
- To evaluate if combining absolute and relative CB thresholds improves CLD diagnostic performance.
- To assess the diagnostic utility of a dual CB threshold criterion.
Main Methods:
- Retrospective analysis of infants (≤6 months) with CB ≥ 1 mg/dL.
- Data from 257 infants were analyzed.
- Receiver operating characteristic (ROC) analysis assessed diagnostic performance of absolute and combined CB thresholds.
Main Results:
- 47 out of 257 infants (18%) were diagnosed with CLD.
- The combined criterion (CB ≥ 1 mg/dL and ≥20% of total bilirubin) showed 100% sensitivity and 61.2% specificity.
- Diagnostic efficiency nearly doubled, reducing the number needed to screen from 5.5 to 2.7.
Conclusions:
- A combined approach using absolute (≥1 mg/dL) and relative (≥20% of total bilirubin) CB thresholds enhances neonatal CLD detection.
- This method maintains full sensitivity while reducing false positives.
- The combined threshold improves diagnostic efficiency in early infancy.
Background:
Conjugated hyperbilirubinemia in early infancy is a critical indicator of hepatobiliary dysfunction. Prompt and accurate identification is essential to diagnose cholestatic liver disease (CLD), particularly biliary atresia. Current guidelines define conjugated bilirubin (CB) ≥ 1 mg/dL as abnormal, irrespective of total bilirubin (TB). This study aimed to evaluate whether combining absolute and relative CB thresholds improves diagnostic performance for CLD.
Methods:
We retrospectively analyzed all infants aged ≤6 months of chronological age with CB ≥ 1 mg/dL admitted to the Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Austria, between January 2004 and February 2025. During that period, 116,104 infants were born at our hospital catchment area; 3119 of these underwent bilirubin fractionation, and 257 infants (0.2% of total births) had a CB ≥ 1 mg/dL and were included in the analysis. Clinical and biochemical data were extracted. Diagnostic performance of the absolute (CB ≥ 1 mg/dL) and in combination with the relative (CB ≥ 20% of TB) thresholds was assessed using receiver operating characteristic (ROC) analysis for the detection of CLD.
Results:
Among 257 infants, 47 (18%) were diagnosed with CLD. The median age at the time of blood sampling was 18 days (IQR 9-31). The combined criterion (CB ≥ 1 mg/dL and ≥20% of TB) achieved 100% sensitivity and 61.2% specificity (AUC = 0.82, 95% CI 0.79-0.92; p < 0.001). Implementation of the combined cut-off reduced the number needed to screen from 5.5 to 2.7, representing nearly a twofold improvement in diagnostic efficiency.
Conclusions:
Applying both absolute (≥1 mg/dL) and relative (≥20% of total bilirubin) CB thresholds substantially improves detection of neonatal CLD in early infancy. This combined approach maintains full sensitivity while reducing false positives and unnecessary investigations, thereby enhancing diagnostic efficiency in early infancy.
Related Concept Videos
Jaundice
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test